News
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both Dravet Syndrome and ALS
BL-001 demonstrated a favorable safety and tolerability profile in healthy volunteers that supports dosing up to 10-fold higher than the efficacious dose level in animal models Dose dependent strain...
Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair
SAN DIEGO, May 17, 2023 – Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis,...
Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome
BL-001 Designed to Replicate the Antiepileptic Effects of the Ketogenic Diet Topline Results including Safety and Tolerability Expected in Third Quarter of 2023 SAN DIEGO, April 25, 2023 – Bloom...
Roya Hakimzadeh Joins Bloom Science as Director of Patient Advocacy
Bloom is excited to welcome Roya Hakimzadeh as Director of Patient Advocacy. Roya joins Bloom with nearly a decade of experience working in rare disease at companies spanning development of small...
Bloom Science Appoints Medicine Development Expert Dr. Stephen Wright to Clinical Advisory Board
SAN DIEGO, Calif., January 4, 2023 -- Dr. Stephen Wright joins Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, as a...
Bloom Science to Develop ALS Biotherapeutics with Exclusive Technology License from Yeda, the Technology Transfer Company of Weizmann Institute of Science
SAN DIEGO, Calif., January 4, 2023 -- Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, and Yeda Research and...